The deal covers Yemen, Syria, Tunisia, Sudan, Morocco, South Sudan, Jordan, Lebanon Libya, Algeria, Iraq and Egypt.
Further details of the agreement were not disclosed.
Hikma Pharma CEO Said Darwazah said Ferinject has been demonstrated to have a powerful impact in the treatment of iron deficiency.
"This agreement enables us to bring another product to patients in the MENA region and we look forward to a long and successful collaboration with Vifor Pharma," Darwazah said.